Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emir Muzurović

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Current Vascular Pharmacology|March 21, 2025
Epicardial Adipose Tissue Modulation: A New Horizon for Sodium-Glucose Cotransporter 2 InhibitorsŠpela Volčanšek, Emir Muzurović
Expert Opinion on Pharmacotherapy|July 23, 2020
Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profileEmir Muzurović, Dimitri P Mikhailidis
Angiology|February 15, 2024
Liver Fibrosis and Atherosclerosis, a Consequence of Metabolic Dysfunction-Do They Share a Similar Pathophysiological Background?Emir Muzurović, Marija Maćešić, Sreten Kavarić
Frontiers in Clinical Diabetes and Healthcare|December 24, 2025
Editorial: Non-insulin pharmacotherapies for the treatment of type 2 diabetes and obesity - old and new playersDimitrios Patoulias, Emir Muzurović, Manfredi Rizzo
Angiology|December 31, 2025
Letter: Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Whisper to the Heart?Emir Muzurović, Ivana Kraljević, Špela Volčanšek
Current Opinion in Cardiology|March 8, 2024
Clinical impact of genetic testing for lipid disordersEmir Muzurović, Sanja Borozan, Manfredi Rizzo
Metabolism: Clinical and Experimental|July 10, 2020
Commentary: From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be basedEmir Muzurović, Dimitri P Mikhailidis, Christos Mantzoros
Journal of Diabetes and Its Complications|November 29, 2022
Obesity and nonalcoholic fatty liver disease in type 1 diabetes mellitus patientsEmir Muzurović, Manfredi Rizzo, Dimitri P Mikhailidis
Current Cardiology Reports|April 13, 2026
Interrelationships Between Key Cardiovascular Risk Factors, Chronic Kidney Disease and Metabolic Dysfunction-Associated Steatotic Liver DiseaseEmir Muzurović, Ksenija Zečević, Dimitri P Mikhailidis
Angiology|April 11, 2026
Letter: Integrating Noninvasive Liver Indices into Risk Stratification of Myocardial Infarction With Non-Obstructive Coronary ArteriesEmir Muzurović, Ksenija Zečević, Christos S Mantzoros
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Current Vascular Pharmacology|March 21, 2025
Epicardial Adipose Tissue Modulation: A New Horizon for Sodium-Glucose Cotransporter 2 InhibitorsŠpela Volčanšek, Emir Muzurović
Expert Opinion on Pharmacotherapy|July 23, 2020
Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profileEmir Muzurović, Dimitri P Mikhailidis
Angiology|February 15, 2024
Liver Fibrosis and Atherosclerosis, a Consequence of Metabolic Dysfunction-Do They Share a Similar Pathophysiological Background?Emir Muzurović, Marija Maćešić, Sreten Kavarić
Frontiers in Clinical Diabetes and Healthcare|December 24, 2025
Editorial: Non-insulin pharmacotherapies for the treatment of type 2 diabetes and obesity - old and new playersDimitrios Patoulias, Emir Muzurović, Manfredi Rizzo
Angiology|December 31, 2025
Letter: Metabolic Dysfunction-Associated Steatotic Liver Disease: A Silent Whisper to the Heart?Emir Muzurović, Ivana Kraljević, Špela Volčanšek
Current Opinion in Cardiology|March 8, 2024
Clinical impact of genetic testing for lipid disordersEmir Muzurović, Sanja Borozan, Manfredi Rizzo
Metabolism: Clinical and Experimental|July 10, 2020
Commentary: From mice to men: In search for dietary interventions to form the background on which pharmacotherapy for non-alcoholic fatty liver disease should be basedEmir Muzurović, Dimitri P Mikhailidis, Christos Mantzoros
Journal of Diabetes and Its Complications|November 29, 2022
Obesity and nonalcoholic fatty liver disease in type 1 diabetes mellitus patientsEmir Muzurović, Manfredi Rizzo, Dimitri P Mikhailidis
Current Cardiology Reports|April 13, 2026
Interrelationships Between Key Cardiovascular Risk Factors, Chronic Kidney Disease and Metabolic Dysfunction-Associated Steatotic Liver DiseaseEmir Muzurović, Ksenija Zečević, Dimitri P Mikhailidis
Angiology|April 11, 2026
Letter: Integrating Noninvasive Liver Indices into Risk Stratification of Myocardial Infarction With Non-Obstructive Coronary ArteriesEmir Muzurović, Ksenija Zečević, Christos S Mantzoros
Pageof 4